CL2021000757A1 - Moduladores de monoacilglicerol lipasa. - Google Patents
Moduladores de monoacilglicerol lipasa.Info
- Publication number
- CL2021000757A1 CL2021000757A1 CL2021000757A CL2021000757A CL2021000757A1 CL 2021000757 A1 CL2021000757 A1 CL 2021000757A1 CL 2021000757 A CL2021000757 A CL 2021000757A CL 2021000757 A CL2021000757 A CL 2021000757A CL 2021000757 A1 CL2021000757 A1 CL 2021000757A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- disorders
- formula
- monoacylglycerol lipase
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Compuestos fusionados de la Fórmula (I) y Fórmula (II), composiciones farmacéuticas que los contienen, métodos para fabricarlos y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con dolor, trastornos psiquiátricos, trastornos neurológicos (que incluyen, pero no se limitan a, trastorno depresivo mayor, depresión resistente al tratamiento, depresión ansiosa, trastorno bipolar), cánceres y afecciones oculares. y ; En donde R1, R2, R2a, R3, R3a, R4 , y R4a se definen en la presente descripción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738600P | 2018-09-28 | 2018-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000757A1 true CL2021000757A1 (es) | 2021-08-27 |
Family
ID=68109428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000757A CL2021000757A1 (es) | 2018-09-28 | 2021-03-25 | Moduladores de monoacilglicerol lipasa. |
Country Status (22)
Country | Link |
---|---|
US (3) | US20200102303A1 (es) |
EP (1) | EP3856178A1 (es) |
KR (1) | KR20210069080A (es) |
CN (1) | CN113164459A (es) |
AU (1) | AU2019350624A1 (es) |
BR (1) | BR112021005896A2 (es) |
CA (1) | CA3111380A1 (es) |
CL (1) | CL2021000757A1 (es) |
CO (1) | CO2021003944A2 (es) |
CR (1) | CR20210153A (es) |
EA (1) | EA202190886A1 (es) |
EC (1) | ECSP21021381A (es) |
IL (1) | IL281812A (es) |
JO (1) | JOP20210058A1 (es) |
MA (1) | MA53721A (es) |
MX (1) | MX2021003737A (es) |
NI (1) | NI202100023A (es) |
PE (1) | PE20211773A1 (es) |
PH (1) | PH12021550659A1 (es) |
SG (1) | SG11202102281VA (es) |
TW (1) | TW202028198A (es) |
WO (1) | WO2020065613A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
MA53722A (fr) | 2018-09-28 | 2022-03-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
EA202190886A1 (ru) | 2018-09-28 | 2021-09-07 | Янссен Фармацевтика Нв | Модуляторы моноацилглицерин-липазы |
CA3156100A1 (en) * | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | MGL PET RADIOLABE LIGANDS |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
AR127955A1 (es) | 2021-12-16 | 2024-03-13 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
AU2003244632A1 (en) | 2002-07-25 | 2004-02-25 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
JP2008510810A (ja) | 2004-08-23 | 2008-04-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としての縮合トリアゾール誘導体 |
WO2006080884A1 (en) | 2005-01-27 | 2006-08-03 | Astrazeneca Ab | Novel biaromatic compounds, inhibitors of the p2x7-receptor |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
AU2008269177A1 (en) | 2007-06-21 | 2008-12-31 | Schering Corporation | Polycyclic Guanine Derivatives and use thereof |
EP2185560A4 (en) | 2007-08-10 | 2011-10-05 | Lundbeck & Co As H | HETEROARYLAMIDANALOGE |
FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
CA2722035C (en) | 2008-04-22 | 2016-10-11 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted p2x7 antagonists |
US8309578B2 (en) | 2008-11-25 | 2012-11-13 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
JP2012524810A (ja) * | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としての複素芳香族及び芳香族ピペラジニルアゼチジニルアミド類 |
JP5654001B2 (ja) | 2009-04-29 | 2015-01-14 | グラクソ グループ リミテッドGlaxo Group Limited | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
EP3176171A1 (en) | 2010-04-02 | 2017-06-07 | Ogeda Sa | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
CN102844507A (zh) | 2010-04-16 | 2012-12-26 | 罗德里戈·格拉夫费尔南德斯 | 用于建筑物的可折叠结构 |
US20130196986A1 (en) | 2010-09-21 | 2013-08-01 | Marc Labroli | Triazolopyrazinones as p2x7 receptor antagonists |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
RU2662436C2 (ru) | 2012-10-15 | 2018-07-26 | Эпизайм, Инк. | Содержащие заместители бензольные соединения |
SI2909192T1 (sl) | 2012-10-16 | 2017-08-31 | Janssen Pharmaceutica Nv | Metilensko vezani kinolinilni modulatorji za ROR-gama-t |
EA031882B1 (ru) | 2012-11-01 | 2019-03-29 | Инсайт Холдингс Корпорейшн | Трициклические конденсированные производные тиофена как ингибиторы jak |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
ES2718495T3 (es) | 2012-12-21 | 2019-07-02 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
DK2964229T3 (da) | 2013-03-06 | 2020-01-27 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren |
NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
SG10201707545XA (en) | 2013-03-14 | 2017-10-30 | Newlink Genetics Corp | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
JP6603649B2 (ja) | 2013-03-14 | 2019-11-06 | キュラデブ ファーマ プライベート リミテッド | キヌレニン経路の阻害剤 |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
EP3511323B1 (en) | 2013-03-14 | 2022-03-02 | GlaxoSmithKline Intellectual Property (No.2) Limited | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
WO2014140075A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
US10053463B2 (en) | 2013-03-14 | 2018-08-21 | Janssen Pharmaceutica Nv | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節物質 |
EP2989103B1 (en) | 2013-03-29 | 2019-02-20 | Ogeda Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
RU2016110021A (ru) | 2013-08-22 | 2017-09-27 | Ф. Хоффманн-Ля Рош Аг | Алкиниловые спирты и способы их применения |
MX2017003254A (es) | 2014-09-11 | 2017-10-12 | Janssen Pharmaceutica Nv | 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina. |
JP6625616B2 (ja) | 2014-09-12 | 2019-12-25 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節n−アシル−トリアゾロピラジン |
ES2714048T3 (es) | 2014-09-12 | 2019-05-24 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
MA53722A (fr) | 2018-09-28 | 2022-03-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
EA202190886A1 (ru) | 2018-09-28 | 2021-09-07 | Янссен Фармацевтика Нв | Модуляторы моноацилглицерин-липазы |
CN112272670B (zh) | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | MGL PET RADIOLABE LIGANDS |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
-
2019
- 2019-09-27 EA EA202190886A patent/EA202190886A1/ru unknown
- 2019-09-27 JO JOP/2021/0058A patent/JOP20210058A1/ar unknown
- 2019-09-27 CR CR20210153A patent/CR20210153A/es unknown
- 2019-09-27 SG SG11202102281VA patent/SG11202102281VA/en unknown
- 2019-09-27 KR KR1020217012874A patent/KR20210069080A/ko unknown
- 2019-09-27 EP EP19780427.1A patent/EP3856178A1/en active Pending
- 2019-09-27 CN CN201980078969.1A patent/CN113164459A/zh active Pending
- 2019-09-27 MX MX2021003737A patent/MX2021003737A/es unknown
- 2019-09-27 AU AU2019350624A patent/AU2019350624A1/en active Pending
- 2019-09-27 PE PE2021000405A patent/PE20211773A1/es unknown
- 2019-09-27 MA MA053721A patent/MA53721A/fr unknown
- 2019-09-27 WO PCT/IB2019/058240 patent/WO2020065613A1/en active Application Filing
- 2019-09-27 BR BR112021005896-6A patent/BR112021005896A2/pt unknown
- 2019-09-27 CA CA3111380A patent/CA3111380A1/en active Pending
- 2019-09-27 US US16/586,088 patent/US20200102303A1/en not_active Abandoned
- 2019-09-27 TW TW108135035A patent/TW202028198A/zh unknown
-
2020
- 2020-12-23 US US17/132,313 patent/US11820766B2/en active Active
-
2021
- 2021-03-22 PH PH12021550659A patent/PH12021550659A1/en unknown
- 2021-03-25 IL IL281812A patent/IL281812A/en unknown
- 2021-03-25 CL CL2021000757A patent/CL2021000757A1/es unknown
- 2021-03-26 EC ECSENADI202121381A patent/ECSP21021381A/es unknown
- 2021-03-26 NI NI202100023A patent/NI202100023A/es unknown
- 2021-03-29 CO CONC2021/0003944A patent/CO2021003944A2/es unknown
-
2022
- 2022-12-06 US US18/062,484 patent/US20230145249A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20210153A (es) | 2021-05-11 |
KR20210069080A (ko) | 2021-06-10 |
US20220332713A1 (en) | 2022-10-20 |
PE20211773A1 (es) | 2021-09-08 |
MA53721A (fr) | 2021-09-15 |
SG11202102281VA (en) | 2021-04-29 |
MX2021003737A (es) | 2021-05-14 |
US11820766B2 (en) | 2023-11-21 |
CO2021003944A2 (es) | 2021-04-19 |
ECSP21021381A (es) | 2021-04-29 |
WO2020065613A1 (en) | 2020-04-02 |
PH12021550659A1 (en) | 2022-02-21 |
JOP20210058A1 (ar) | 2021-03-24 |
TW202028198A (zh) | 2020-08-01 |
IL281812A (en) | 2021-05-31 |
CN113164459A (zh) | 2021-07-23 |
JP2022502424A (ja) | 2022-01-11 |
CA3111380A1 (en) | 2020-04-02 |
US20200102303A1 (en) | 2020-04-02 |
NI202100023A (es) | 2021-09-07 |
AU2019350624A1 (en) | 2021-03-18 |
US20230145249A1 (en) | 2023-05-11 |
EP3856178A1 (en) | 2021-08-04 |
EA202190886A1 (ru) | 2021-09-07 |
BR112021005896A2 (pt) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021003944A2 (es) | Moduladores de monoacilglicerol lipasa | |
ECSP22062460A (es) | Moduladores de la monoacilglicerol lipasa | |
MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
GT200800105A (es) | Triazolopiridazinas como moduladores de tirosina cinasa | |
DOP2017000309A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico | |
MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
CO2020002959A2 (es) | Moduladores de piruvato quinasas y uso de los mismos | |
NI200900192A (es) | Derivados de 2-piridina carboxamidas como moduladores de canal de sodio. | |
AR057887A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
CR20130415A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
CO2022008675A2 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
CO2021011919A2 (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes | |
CL2020001564A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. | |
ECSP19072975A (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
CL2023001195A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. | |
PE20230106A1 (es) | Compuestos de pirimidina fusionados como moduladores de kcc2 | |
CO6280529A2 (es) | DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA | |
CL2023000352A1 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos | |
CO2021017740A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
PE20141184A1 (es) | Moduladores alostericos positivos del receptor de acetilcolina nicotinico |